Nucynta ER approved as neuropathic pain treatment for DPN patients
RARITAN, N.J. — The Food and Drug Administration has approved a supplemental new drug application for an opioid analgesic to treat diabetes-related pain.
Johnson & Johnson subsidiary Janssen Pharmaceuticals said Nucynta (tapentadol) extended-release tablets has been approved for the management of neuropathic pain associated with diabetic peripheral neuropathy in adults when a continuous, around-the-clock opioid analgesic is needed for an extended period of time. Nucynta ER currently is the only FDA-approved opioid for neuropathic pain associated with DPN, Janssen said.
"The approval of Nucynta ER for DPN pain represents the ongoing commitment of Janssen to bring new and innovative products to patients and physicians for the management of pain," Janssen Pharmaceuticals VP medical affairs Paul Chang said. "It is exciting that our in-depth experience in pain management allows us to continue to provide patients with effective options to treat their pain."
Lilly ceases clinical research of pomaglumetad methionil as schizophrenia treatment
INDIANAPOLIS — Eli Lilly has ceased ongoing clinical studies of an investigational treatment for schizophrenia.
The drug maker said that after recently conducting an independent futility analysis, it concluded that the second of Lilly’s two pivotal studies "was unlikely to be positive in its primary efficacy endpoint if enrolled to completion." Additionally, the recently completed phase-2 study, which investigated pomaglumetad methionil (also known as mGlu2/3) as an adjunctive treatment with atypical antipsychotics, did not meet its primary endpoint.
"I’m disappointed in what these results mean for patients with schizophrenia who still are searching for options to treat this terrible illness," said Jan Lundberg, Lilly EVP science and technology, and Lilly Research Labs president. "While there are many challenges in this complex field of research, neuroscience remains a core area of focus at Lilly. Our clinical development pipeline includes nearly a dozen neuroscience molecules being studied to treat illnesses, such as depression, bipolar disorder and cognitive impairment associated with schizophrenia."
Puffs partners with Dress for Success to help women put best faces forward
CINCINNATI — A facial tissue brand has partnered with an organization that promotes the economic independence of disadvantaged women.
Puffs announced that it has partnered with Dress for Success to provide beauty makeovers for deserving women across the country. Through Oct. 12, Puffs is hosting a tab on its Facebook page, which will allow people to upload their inspirational quotes, tips and stories on how they put "their best face forward" every day. As fans submit their tip — which will be hosted on a gallery within the tab — Puffs will donate $1 per upload to Dress for Success Worldwide to help promote the economic independence of disadvantaged women. What’s more, with every entry, fans will be entered into a sweepstakes to win 1-of-60 Procter & Gamble beauty baskets, as well as a grand-prize trip to New York for a beauty makeover.
"Like Puffs, Dress for Success aims to help women get a fresh new start in both work and in life," Puffs communications manager Laura Dressman said. "We’re proud to partner with such an uplifting organization and hope fans everywhere engage in the motivating tips on our Facebook page to help us honor the beauty in all women."
Throughout the program, Puffs and Dress for Success also will host local events in Chicago and San Francisco, as well as a finale event in New York, offering Dress for Success clients in attendance wardrobe and beauty makeovers.
"Dress for Success helps provide women with the tools they need to succeed both personally and professionally," Dress for Success Worldwide CEO Joi Gordon said. "Through this exciting new partnership with Puffs, our women will receive the confidence they need to put their best face forward as they re-enter the workforce."